Nuvig Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Nuvig Therapeutics's estimated annual revenue is currently $2.7M per year.
- Nuvig Therapeutics's estimated revenue per employee is $93,534
- Nuvig Therapeutics's total funding is $208M.
Employee Data
- Nuvig Therapeutics has 29 Employees.
- Nuvig Therapeutics grew their employee count by 45% last year.
Nuvig Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Staff & Executive Assistant | Reveal Email/Phone |
2 | VP, Development Operations | Reveal Email/Phone |
3 | VP, Development Operations | Reveal Email/Phone |
4 | Director CMC Biologics Manufacturing | Reveal Email/Phone |
5 | Associate Director Operations | Reveal Email/Phone |
6 | Senior Director Analytical Development | Reveal Email/Phone |
7 | Senior Director Analytical Development | Reveal Email/Phone |
Nuvig Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.4M | 70 | -8% | $53M | N/A |
#2 | $32.4M | 167 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.8M | 18 | 13% | N/A | N/A |
#5 | $0.8M | 5 | -50% | N/A | N/A |
#6 | $0.8M | 10 | 0% | N/A | N/A |
#7 | $14M | 90 | -12% | N/A | N/A |
#8 | $0.4M | 336 | 10% | $236.7M | N/A |
#9 | $4.8M | 62 | -74% | $160M | N/A |
#10 | $3.7M | 24 | -8% | N/A | N/A |
What Is Nuvig Therapeutics?
Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following in?ammation, and improve the treatment options for patients. Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.
keywords:N/A$208M
Total Funding
29
Number of Employees
$2.7M
Revenue (est)
45%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $3.2M | 29 | 12% | N/A |
#2 | $2.9M | 29 | -3% | N/A |
#3 | $5M | 29 | -15% | N/A |
#4 | $5.9M | 29 | -6% | N/A |
#5 | $6.5M | 30 | N/A | N/A |